Press & News
Affibodys partnering strategy is to engage in partnerships centered around:
- Target-by-target development of novel biotherapeutics (discovery collaborations), or
- Out-licensing of Albumod™ technology
For opportunities for collaborative, partnership or licensing agreements, please contact firstname.lastname@example.org.
Affibodys latest Press releases
Affibody in short
Affibody is a Swedish biotech company focused on developing next generation biopharmaceuticals based on its unique proprietary technology platforms: Affibody® molecules and Albumod™.
Upcoming reports Financial calendar
- Year-end report (February 24, 2017)